Clarity PharmaceuticalsAustralia, a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health, USA,  announced that they have entered into an agreement covering Clarity’s Targeted Copper Theranostics (TCT) platform.

Cardinal Health will provide cGMP product manufacturing of ready-to-use TCT for Clarity’s U.S.-based clinical trials from its Center for Theranostics Advancement in Indianapolis, Indiana. TCT are investigational radiopharmaceuticals that pair copper-64 (64Cu) and copper-67 (67Cu) for diagnosis and therapy.

To read more please visit:

Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics

Source: CLARITY